Citadel Advisors - ARCUTIS BIOTHERAPEUTICS INC ownership

ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of ARCUTIS BIOTHERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,521,501
+41.2%
286,535
+153.3%
0.00%
Q2 2023$1,077,920
-67.1%
113,108
-62.0%
0.00%
-100.0%
Q1 2023$3,278,231
+604.7%
298,021
+848.1%
0.00%
Q4 2022$465,208
-69.8%
31,433
-61.0%
0.00%
Q3 2022$1,539,000
-65.7%
80,515
-61.7%
0.00%
-100.0%
Q2 2022$4,483,000
+9.6%
210,411
-0.9%
0.00%0.0%
Q1 2022$4,091,000
-29.5%
212,400
-24.1%
0.00%0.0%
Q4 2021$5,806,000
-14.9%
279,915
-2.0%
0.00%0.0%
Q3 2021$6,826,000
-46.4%
285,732
-38.7%
0.00%
-66.7%
Q2 2021$12,725,000
-2.8%
466,312
+3.1%
0.00%0.0%
Q1 2021$13,089,000
+248.0%
452,456
+238.4%
0.00%
+200.0%
Q4 2020$3,761,000
+735.8%
133,703
+771.0%
0.00%
Q3 2020$450,000
-55.0%
15,350
-53.6%
0.00%
Q2 2020$1,000,000
-39.6%
33,089
-40.4%
0.00%
-100.0%
Q1 2020$1,656,00055,5650.00%
Other shareholders
ARCUTIS BIOTHERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Frazier Life Sciences Management, L.P. 8,684,232$165,956,00012.78%
Bain Capital Life Sciences Investors, LLC 3,000,000$57,330,0006.84%
Pivotal bioVenture Partners Investment Advisor LLC 569,041$10,874,0003.97%
Logos Global Management LP 1,525,000$29,143,0003.58%
1492 Capital Management LLC 178,320$3,408,0002.45%
Cormorant Asset Management, LP 1,000,000$19,110,0001.34%
MPM BioImpact LLC 257,185$4,915,0001.16%
Orbimed Advisors 2,800,000$53,508,0000.99%
SECTORAL ASSET MANAGEMENT INC 220,985$4,223,0000.83%
Rubric Capital Management LP 472,047$9,021,0000.45%
View complete list of ARCUTIS BIOTHERAPEUTICS INC shareholders